Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan’s MHLW Steps Up Efforts To Reduce Drug Approval Lag Time

This article was originally published in PharmAsia News

Executive Summary

TOKYO - On the back of rising pressures, Japan's Ministry of Health, Labor and Welfare is stepping up efforts to shorten new drug approval periods that now are woefully behind other countries - yet finds the undertaking a tall task that may take longer than officials envisioned

You may also be interested in...



Japan's MHLW Enhances Role Of Innovation In Drug Pricing, USTR Says

WASHINGTON - Japan is giving more weight to innovation when pricing new drugs

Japan's MHLW Enhances Role Of Innovation In Drug Pricing, USTR Says

WASHINGTON - Japan is giving more weight to innovation when pricing new drugs

Japan's Health Ministry Improves Drug Pricing For Innovators

Japanese agency creates new anti-cancer drugs division and adds personnel to speed up drug reviews, U. S. Trade Representative reports.

Related Content

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel